Alnylam Pharmaceuticals, Inc. (ALNY) Position Reduced by Credit Agricole S A
Credit Agricole S A cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 75.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,316 shares of the biopharmaceutical company’s stock after selling 10,030 shares during the period. Credit Agricole S A’s holdings in Alnylam Pharmaceuticals were worth $125,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in ALNY. State Street Corp increased its stake in shares of Alnylam Pharmaceuticals by 1.2% in the fourth quarter. State Street Corp now owns 2,361,998 shares of the biopharmaceutical company’s stock worth $88,430,000 after buying an additional 28,822 shares during the last quarter. BlackRock Fund Advisors increased its stake in shares of Alnylam Pharmaceuticals by 3.0% in the third quarter. BlackRock Fund Advisors now owns 1,927,337 shares of the biopharmaceutical company’s stock worth $130,635,000 after buying an additional 56,455 shares during the last quarter. RTW Investments LLC increased its stake in shares of Alnylam Pharmaceuticals by 13.9% in the third quarter. RTW Investments LLC now owns 948,286 shares of the biopharmaceutical company’s stock worth $64,275,000 after buying an additional 115,737 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its stake in shares of Alnylam Pharmaceuticals by 7.0% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 502,776 shares of the biopharmaceutical company’s stock worth $34,078,000 after buying an additional 33,020 shares during the last quarter. Finally, Frontier Capital Management Co. LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $8,871,000. 88.70% of the stock is currently owned by institutional investors and hedge funds.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded down 1.72% during mid-day trading on Friday, reaching $49.59. The company’s stock had a trading volume of 459,817 shares. The firm has a 50-day moving average of $51.36 and a 200-day moving average of $44.53. The firm’s market capitalization is $4.27 billion. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $80.11.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, February 8th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.34) by $0.02. The firm had revenue of $17.50 million for the quarter, compared to the consensus estimate of $10.66 million. Alnylam Pharmaceuticals had a negative net margin of 869.63% and a negative return on equity of 37.25%. The business’s quarterly revenue was up 130.3% on a year-over-year basis. During the same quarter last year, the firm posted ($1.07) EPS. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.16) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/04/21/credit-agricole-s-a-cuts-stake-in-alnylam-pharmaceuticals-inc-alny-updated-updated.html.
A number of equities analysts have issued reports on ALNY shares. Vetr downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $46.27 price target on the stock. in a research report on Thursday, January 5th. Credit Suisse Group AG downgraded Alnylam Pharmaceuticals to a “hold” rating and set a $50.00 price target on the stock. in a research report on Monday, March 20th. BMO Capital Markets started coverage on Alnylam Pharmaceuticals in a research report on Monday. They set an “outperform” rating and a $73.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $68.00 price target (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 9th. Finally, JMP Securities set a $69.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 3rd. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $64.97.
In related news, Director Philip A. Sharp sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, January 25th. The shares were sold at an average price of $37.95, for a total value of $569,250.00. Following the transaction, the director now owns 155,795 shares in the company, valued at approximately $5,912,420.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.00% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.